DK176168B1 - Terapeutisk præparat til behandling af chocktilstande ved perfusion - Google Patents

Terapeutisk præparat til behandling af chocktilstande ved perfusion Download PDF

Info

Publication number: DK176168B1
Authority: DK; Denmark
Prior art keywords: perfusion; treatment; vascular; compositions; shock
Prior art date: 1989-12-22

Application number

DK199003041A

Other languages

Danish (da)

English (en)

Other versions

DK304190D0 (da

DK304190A (da

Inventor

Pierre Braquet

Chabrier De Las Pierre-Etienne

Jean-Michel Guillon

Michel Auguet

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-22

Filing date

1990-12-21

Publication date

2006-11-13

1990-12-21 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

1990-12-21 Publication of DK304190D0 publication Critical patent/DK304190D0/da

1991-06-23 Publication of DK304190A publication Critical patent/DK304190A/da

2006-11-13 Application granted granted Critical

2006-11-13 Publication of DK176168B1 publication Critical patent/DK176168B1/da

Links

230000035939 shock Effects 0.000 title claims description 10
238000011282 treatment Methods 0.000 title claims description 8
230000010412 perfusion Effects 0.000 title claims description 7
230000001225 therapeutic effect Effects 0.000 title claims description 4
238000002360 preparation method Methods 0.000 title description 3
239000000203 mixture Substances 0.000 claims description 22
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 18
229960001138 acetylsalicylic acid Drugs 0.000 claims description 13
239000002981 blocking agent Substances 0.000 claims description 13
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 12
150000001875 compounds Chemical class 0.000 claims description 10
229960000905 indomethacin Drugs 0.000 claims description 9
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 7
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 2
230000002792 vascular Effects 0.000 description 17
230000000694 effects Effects 0.000 description 11
KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 9
NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 7
NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 7
239000002158 endotoxin Substances 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000004046 hyporesponsiveness Effects 0.000 description 5
208000001953 Hypotension Diseases 0.000 description 4
206010040047 Sepsis Diseases 0.000 description 4
206010040070 Septic Shock Diseases 0.000 description 4
210000003038 endothelium Anatomy 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000036543 hypotension Effects 0.000 description 4
229960001802 phenylephrine Drugs 0.000 description 4
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
102000002045 Endothelin Human genes 0.000 description 3
108050009340 Endothelin Proteins 0.000 description 3
208000037487 Endotoxemia Diseases 0.000 description 3
WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 3
206010047141 Vasodilatation Diseases 0.000 description 3
150000001483 arginine derivatives Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229960005192 methoxamine Drugs 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 2
UYZFAUAYFLEHRC-LURJTMIESA-N L-NIO Chemical compound CC(N)=NCCC[C@H](N)C(O)=O UYZFAUAYFLEHRC-LURJTMIESA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
229930064664 L-arginine Natural products 0.000 description 2
235000014852 L-arginine Nutrition 0.000 description 2
UYZFAUAYFLEHRC-UHFFFAOYSA-N NG-iminoethyl-L-ornithine Natural products CC(N)=NCCCC(N)C(O)=O UYZFAUAYFLEHRC-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000003862 amino acid derivatives Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
150000003943 catecholamines Chemical class 0.000 description 2
230000008602 contraction Effects 0.000 description 2
230000001120 cytoprotective effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000005555 hypertensive agent Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000005526 vasoconstrictor agent Substances 0.000 description 2
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010018873 Haemoconcentration Diseases 0.000 description 1
125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 1
206010044541 Traumatic shock Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
-1 arginine compound Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009989 contractile response Effects 0.000 description 1
230000001595 contractor effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940124645 emergency medicine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000000034 method Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000036513 peripheral conductance Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polyurethanes Or Polyureas (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK199003041A 1989-12-22 1990-12-21 Terapeutisk præparat til behandling af chocktilstande ved perfusion DK176168B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8929076		1989-12-22
GB898929076A GB8929076D0 (en)	1989-12-22	1989-12-22	Treatment of shock by blocking agents of edrf effect or formation

Publications (3)

Publication Number	Publication Date
DK304190D0 DK304190D0 (da)	1990-12-21
DK304190A DK304190A (da)	1991-06-23
DK176168B1 true DK176168B1 (da)	2006-11-13

Family

ID=10668428

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK199003041A DK176168B1 (da)	1989-12-22	1990-12-21	Terapeutisk præparat til behandling af chocktilstande ved perfusion

Country Status (21)

Country	Link
US (1)	US5081148A (fr)
JP (1)	JP2706578B2 (fr)
KR (1)	KR950005866B1 (fr)
AT (1)	AT403122B (fr)
AU (1)	AU629777B2 (fr)
BE (1)	BE1005531A5 (fr)
CA (1)	CA2032904C (fr)
CH (1)	CH681692A5 (fr)
DE (1)	DE4041283C2 (fr)
DK (1)	DK176168B1 (fr)
FR (1)	FR2656220B1 (fr)
GB (2)	GB8929076D0 (fr)
HK (1)	HK134693A (fr)
IE (1)	IE64403B1 (fr)
IT (1)	IT1246511B (fr)
LU (1)	LU87867A1 (fr)
MY (1)	MY105328A (fr)
NL (1)	NL194717C (fr)
OA (1)	OA09337A (fr)
SE (1)	SE504922C2 (fr)
ZA (1)	ZA9010004B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE468881B (sv) *	1991-01-09	1993-04-05	Kabi Pharmacia Ab	Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
GB9127376D0 (en) *	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
GB9200114D0 (en) *	1992-01-04	1992-02-26	Scras	Dual inhibitors of no synthase and cyclooxygenase
US5385940A (en) *	1992-11-05	1995-01-31	The General Hospital Corporation	Treatment of stroke with nitric-oxide releasing compounds
US5585402A (en) *	1992-12-23	1996-12-17	Glaxo Wellcome Inc.	Nitric oxide synthase inhibitors
US5436270A (en) *	1993-04-07	1995-07-25	National Science Council	Method for protecting against endotoxin-induced shock
GB9312204D0 (en) *	1993-06-14	1993-07-28	Zeneca Ltd	Therapeutic composition
GB9312761D0 (en) *	1993-06-21	1993-08-04	Wellcome Found	Amino acid derivatives
US6297276B1 (en)	1993-10-04	2001-10-02	Glaxosmithkline	Substituted urea and isothiourea derivatives as no synthase inhibitors
US6090846A (en) *	1994-06-01	2000-07-18	Glaxo Wellcome Inc.	Substituted urea and isothiourea derivatives as no synthase inhibitors
US6225305B1 (en)	1993-10-04	2001-05-01	Glaxo Wellcome Inc.	Substituted urea and isothiorea derivatives as no synthase inhibitors
EP0724435B1 (fr) *	1993-10-21	2002-08-14	G.D. Searle & Co.	Derives amidino utiles comme inhibiteurs de l'oxyde nitrique-synthase
ATE177078T1 (de) *	1993-10-21	1999-03-15	Searle & Co	Amidino-derivate als no-synthetase inhibitoren
GB9404400D0 (en) *	1994-03-07	1994-04-20	Wood Pauline J	Potentiation of bioreductive agents
ES2151055T3 (es) *	1994-03-10	2000-12-16	Searle & Co	Derivados de l-n6-(1-iminoetil)lisina utiles como inhibidores de oxido nitrico sintasa.
US5684008A (en)	1994-11-09	1997-11-04	G. D. Searle & Co.	Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
FR2727111B1 (fr) *	1994-11-21	1997-01-17	Hoechst Lab	Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
JPH10510540A (ja) *	1994-12-12	1998-10-13	オメロスメディカルシステムズ，インコーポレーテッド	灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
RU2180852C2 (ru) *	1994-12-12	2002-03-27	Омерос Медикл Системс, Инк.	Ингибирующий раствор и способ подавления боли, воспаления или спазма
KR100517210B1 (ko) *	1994-12-12	2006-06-07	오메로스 코포레이션	통증,염증및경련억제용관주용액
FR2730930B1 (fr)	1995-02-27	1997-04-04	Oreal	Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique
GB9504350D0 (en) *	1995-03-04	1995-04-26	Sod Conseils Rech Applic	Arginine derivatives
ATE246678T1 (de) *	1995-04-20	2003-08-15	Searle & Co	Zyclische amidino mittel als stickstoffoxid- synthase inhibitoren
US5830917A (en) *	1995-09-11	1998-11-03	G. D. Searle & Co.	L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) *	1996-03-06	1999-11-09	G.D. Searle & Co.	Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) *	1996-03-06	1999-08-31	G.D. Searle & Co.	Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US6369272B1 (en)	1997-01-13	2002-04-09	Glaxosmithkline	Nitric oxide synthase inhibitors
US6620848B2 (en)	1997-01-13	2003-09-16	Smithkline Beecham Corporation	Nitric oxide synthase inhibitors
US5981556A (en) *	1997-07-22	1999-11-09	G.D. Searle & Co.	1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
JP2002517502A (ja)	1998-06-10	2002-06-18	ジー・ディー・サール・アンド・カンパニー	複素二環状及び三環状一酸化窒素シンターゼ阻害剤
US6344473B1 (en)	2000-08-07	2002-02-05	G.D. Searle & Co.	Imidazoles useful as nitric oxide synthase inhibitors
CA2552195C (fr)	2003-12-30	2012-01-24	Vasopharm Biotech Gmbh	4-amino-7,8-dihydropteridines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter des maladies causees par une augmentation du niveau d'oxyde nitrique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB931921A (en) *	1960-12-22	1963-07-24	Lab Roques	Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE1767212B1 (de) *	1967-04-13	1971-05-06	Sumitomo Chemical Co	Verfahren zur Herstellung injizierbarer Arzneimittel
FR2115060A1 (en) *	1970-11-26	1972-07-07	Metabio	Freeze-dried acetylsalicylates of lysine and arginine - easily prepd derivs of aspirin
CA1029660A (fr) *	1973-06-01	1978-04-18	Kyowa Hakko Kogyo Co.	Prevention des lesions gastriques
FR2320759A1 (fr) *	1975-08-11	1977-03-11	Union Pharma Scient Appl	Solution d'acide acetylsalicylique extemporanee injectable
IT1127322B (it) *	1979-12-28	1986-05-21	Italfarmaco Spa	Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
IT1127321B (it) *	1979-12-28	1986-05-21	Italfarmaco Spa	Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
JPS5781409A (en) *	1980-11-10	1982-05-21	Toko Yakuhin Kogyo Kk	External plaster
JPS57197211A (en) *	1981-05-28	1982-12-03	Sumitomo Chem Co Ltd	Useful eye drop composition
JPS57200361A (en) *	1981-06-03	1982-12-08	Sumitomo Chem Co Ltd	"indomethacin(r)" pharmaceutical with low irritant action
JPS6239524A (ja) *	1985-08-13	1987-02-20	Toko Yakuhin Kogyo Kk	消炎鎮痛軟膏剤
JPH0236570B2 (ja) *	1985-05-30	1990-08-17	Toko Yakuhin Kogyo Kk	Shoenchintsunankozai
IT1201511B (it) *	1985-12-23	1989-02-02	Italfarmaco Spa	Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono
AU1489688A (en) *	1987-02-20	1988-09-14	Shriners Hospitals For Crippled Children	Omega-3 fatty acids in traumatic injury treatment

1989
- 1989-12-22 GB GB898929076A patent/GB8929076D0/en active Pending
1990
- 1990-12-11 NL NL9002720A patent/NL194717C/nl not_active IP Right Cessation
- 1990-12-12 ZA ZA9010004A patent/ZA9010004B/xx unknown
- 1990-12-12 SE SE9003974A patent/SE504922C2/sv not_active IP Right Cessation
- 1990-12-14 BE BE9001200A patent/BE1005531A5/fr not_active Expired - Fee Related
- 1990-12-18 IT IT02241390A patent/IT1246511B/it active IP Right Grant
- 1990-12-19 US US07/630,273 patent/US5081148A/en not_active Expired - Lifetime
- 1990-12-19 IE IE459290A patent/IE64403B1/en not_active IP Right Cessation
- 1990-12-19 FR FR9015904A patent/FR2656220B1/fr not_active Expired - Fee Related
- 1990-12-19 CH CH4034/90A patent/CH681692A5/fr not_active IP Right Cessation
- 1990-12-20 AT AT0260690A patent/AT403122B/de not_active IP Right Cessation
- 1990-12-20 MY MYPI90002223A patent/MY105328A/en unknown
- 1990-12-21 OA OA59932A patent/OA09337A/fr unknown
- 1990-12-21 DK DK199003041A patent/DK176168B1/da not_active IP Right Cessation
- 1990-12-21 AU AU68376/90A patent/AU629777B2/en not_active Ceased
- 1990-12-21 LU LU87867A patent/LU87867A1/fr unknown
- 1990-12-21 KR KR1019900021355A patent/KR950005866B1/ko not_active IP Right Cessation
- 1990-12-21 DE DE4041283A patent/DE4041283C2/de not_active Expired - Fee Related
- 1990-12-21 CA CA002032904A patent/CA2032904C/fr not_active Expired - Lifetime
- 1990-12-24 GB GB9028013A patent/GB2240041B/en not_active Expired - Lifetime
- 1990-12-25 JP JP2419113A patent/JP2706578B2/ja not_active Expired - Lifetime
1993
- 1993-12-09 HK HK1346/93A patent/HK134693A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ZA9010004B (en)	1991-10-30
OA09337A (fr)	1992-09-15
AT403122B (de)	1997-11-25
FR2656220A1 (fr)	1991-06-28
SE9003974L (sv)	1991-06-23
GB8929076D0 (en)	1990-02-28
KR950005866B1 (ko)	1995-06-02
GB2240041A (en)	1991-07-24
DE4041283A1 (de)	1991-06-27
JPH04364124A (ja)	1992-12-16
SE504922C2 (sv)	1997-05-26
JP2706578B2 (ja)	1998-01-28
KR910011253A (ko)	1991-08-07
CA2032904C (fr)	1996-01-02
AU6837690A (en)	1991-06-27
MY105328A (en)	1994-09-30
SE9003974D0 (sv)	1990-12-12
US5081148A (en)	1992-01-14
NL194717C (nl)	2003-01-07
IE64403B1 (en)	1995-08-09
GB9028013D0 (en)	1991-02-13
DK304190D0 (da)	1990-12-21
DE4041283C2 (de)	2000-07-13
NL9002720A (nl)	1991-07-16
DK304190A (da)	1991-06-23
LU87867A1 (fr)	1991-05-07
HK134693A (en)	1993-12-17
GB2240041B (en)	1993-09-01
IT9022413A1 (it)	1991-06-23
IT1246511B (it)	1994-11-19
AU629777B2 (en)	1992-10-08
IT9022413A0 (it)	1990-12-18
NL194717B (nl)	2002-09-02
FR2656220B1 (fr)	1995-01-13
BE1005531A5 (fr)	1993-09-28
CH681692A5 (fr)	1993-05-14
ATA260690A (de)	1997-04-15
CA2032904A1 (fr)	1991-06-23
IE904592A1 (en)	1991-07-03

Legal Events

Date	Code	Title	Description
2010-08-09	PBP	Patent lapsed	Country of ref document: DK

Publication	Publication Date	Title
DK176168B1 (da)	2006-11-13	Terapeutisk præparat til behandling af chocktilstande ved perfusion
KR20190073365A (ko)	2019-06-26	사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
RU2004109920A (ru)	2005-04-20	Фармацевтическая композиция, включающая лумиракоксиб
US20220273754A1 (en)	2022-09-01	Ss-31 for the prevention and/or treatment of aneurysm
IL268930B1 (en)	2024-05-01	Citrulline for the treatment of sickle cell crisis
KR20120089623A (ko)	2012-08-13	정맥내 투여용 이부프로펜을 이용한 환자의 치료
JPH07504410A (ja)	1995-05-18	（ｒ）−２−（３−ベンゾイルフェニル）プロピオン酸を含有する鎮痛剤として有用な薬学的組成物
WO2021246868A1 (fr)	2021-12-09	Composés chromanol, quinone ou hydroquinone pour le traitement de la septicémie
EP3851104A1 (fr)	2021-07-21	Combinaison pharmaceutique synergique d'un inhibiteur sélectif de la cyclooxygénase 2 et d'un dérivé d'anthraquinone
ES2300856T3 (es)	2008-06-16	El uso de cistina o cisteina para la prevencion y el tratamiento de estres oxidativo provocado por hemodialisis en pacientes con enfermedad renal aguda o cronica.
CA2492378A1 (fr)	2004-01-22	Aminoacide modifie pour inhiber l'agregation plaquettaire
Patscheke et al.	1987	Inhibition of platelet activation by the novel thromboxane receptor antagonist BM 13.505
CA3144895A1 (fr)	2021-01-07	Procedes de polytherapie, compositions et kits
KR20080096829A (ko)	2008-11-03	정맥내 항바이러스 치료
JPS62123119A (ja)	1987-06-04	眼手術時の縮瞳抑制剤
CA2515505A1 (fr)	2004-08-19	Inhibiteur de l'augmentation du taux de glycemie peri-operatoire
JP2004535457A (ja)	2004-11-25	ピリダジノン誘導体の新しい用途
ES2280589T3 (es)	2007-09-16	Uso de derivados de acido 4-oxobutanoico en el tratamiento de la inflamacion.
WO1999004783A1 (fr)	1999-02-04	Composition destinee a proteger des lesions causees par l'ischemie
CN102526035A (zh)	2012-07-04	一种用于制备抗脑血管疾病药物的组合物
CN114306299A (zh)	2022-04-12	贝利司他在制备缓解和/或治疗缺血性脑卒中药物中的应用
EP4376956A1 (fr)	2024-06-05	Compositions pharmaceutiques à base de sulfonamide aromatique halo actif à usage interne
WO2023152500A1 (fr)	2023-08-17	Combinaison de composés destinée au traitement de maladies vasculaires comprenant un inhibiteur de pde5, de l'arginine et de la n-acétylcystéine
AU2023219232A1 (en)	2024-07-25	Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
US20220304999A1 (en)	2022-09-29	Rebamipide for use in prevention and/or treatment of arterial stiffness